A. Gonzalez-Rodriguez

发表

NK Cell-Based Immunotherapy in Cancer Metastasis

M. Vitale, A. López-Soto, S. González, 2018, Cancers.

Molecular Bases for the Regulation of NKG2D Ligands in Cancer

A. López-Soto, S. González, A. Gonzalez-Rodriguez, 2014, Front. Immunol..

Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

J. Briones, A. López-Guillermo, M. Terol, 2018, British journal of haematology.

Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice

V. Anttila, K. Sullivan, A. Cuneo, 2021, Human vaccines & immunotherapeutics.

Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.

N. Puig, A. Oriol, B. Paiva, 2022, Clinical lymphoma, myeloma & leukemia.

Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)

N. Puig, J. de la Rubia, L. Rosiñol, 2022, Leukemia & lymphoma.

BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia

A. López-Soto, S. González, S. Lorenzo-Herrero, 2021, Cancers.

Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells

Á. Payer, A. López-Soto, S. González, 2014, BioMed research international.

Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding

T. Spies, C. López-Larrea, V. Groh, 2012, Cancer Immunology, Immunotherapy.

The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling

Á. Payer, A. López-Soto, S. González, 2019, Front. Immunol..

Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients

J. Sancho, Á. Payer, A. Gonzalez-Rodriguez, 2016, Leukemia & lymphoma.

Checkpoint inhibition in the fight against cancer: NK cells have some to say in it

S. González, S. Lorenzo-Herrero, C. Sordo-Bahamonde, 2021, Successes and Challenges of NK Immunotherapy.

NK Cells in the Treatment of Hematological Malignancies

S. González, S. Lorenzo-Herrero, C. Sordo-Bahamonde, 2019, Journal of clinical medicine.

Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia

Á. Payer, A. López-Soto, S. González, 2018, Front. Immunol..

Conceptual aspects of self and nonself discrimination.

B. Suarez-Alvarez, C. López-Larrea, A. López-Soto, 2011, Self/nonself.

Immune Response and Immunotherapy in Chronic Lymphocytic Leukemia

A. López-Soto, S. González, A. Gonzalez-Rodriguez, 2012 .

14 Immune Response and Immunotherapy in Chronic Lymphocytic Leukemia

A. López-Soto, S. González, A. Gonzalez-Rodriguez, 2012 .

Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease

Á. Payer, A. López-Soto, S. González, 2014, PloS one.

Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia

Andrea Acebes-Huerta, Azahara Fernández-Guizán, A. López-Soto, 2010, Leukemia & lymphoma.

Driver Mutations and Single Copy Number Abnormalities Identify Binet Stage A Patients with Chronic Lymphocytic Leukemia with Aggressive Progression

Á. Payer, S. González, S. Lorenzo-Herrero, 2020, Journal of clinical medicine.

Lenalidomide and Chronic Lymphocytic Leukemia

Á. Payer, S. González, A. Gonzalez-Rodriguez, 2013, BioMed research international.

Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy

J. Sancho, Á. Payer, A. Gonzalez-Rodriguez, 2015, Leukemia & lymphoma.

Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia

Á. Payer, A. López-Soto, S. González, 2017, Oncoimmunology.

LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia

Á. Payer, A. López-Soto, S. González, 2021, Cancers.

Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma

C. Martínez, Arturo Pereira, R. García-Sanz, 2022, Annals of Hematology.

Analysis of clinical prognostic variables for Chronic Lymphocytic Leukemia decision-making problems

Enrique J. deAndrés-Galiana, Oscar Luaces, Juan Luis Fernández Martínez, 2016, J. Biomed. Informatics.

A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma.

N. Puig, M. Calasanz, A. Oriol, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia

Á. Payer, A. López-Soto, S. González, 2023, Cancer Immunology, Immunotherapy.

Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience.

J. S. San Miguel, J. Bladé, J. Lahuerta, 2021, Clinical lymphoma, myeloma & leukemia.

Chemo-Immunotherapy: A New Trend in Cancer Treatment

J. García-Pedrero, J. Rodrigo, S. González, 2023, Cancers.

Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients

J. Sancho, Á. Payer, A. Gonzalez-Rodriguez, 2016, Leukemia & lymphoma.